Payment overview · 2025
General Payments
$905.64
44 reported records · 17 companies
Healthcare provider profile · identity verified
Sidney Boyd Chadwell, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · PALESTINE, TX · NPI 1902827801
Verified facts
What the public records show
CMS Open Payments records show Sidney Boyd Chadwell, D.O. received $905.64 in general payments during 2025 across 44 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $207.56 | 22.9% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $134.73 | 14.9% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $110.41 | 12.2% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $103.21 | 11.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $76.82 | 8.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.67 | 4.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $36.43 | 4.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.93 | 3.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.70 | 3.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.02 | 2.5% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.49 | 2.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.26 | 2.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.10 | 1.9% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $16.97 | 1.9% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.88 | 1.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.52 | 1.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.94 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $860.64 | 43 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $224.00 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $134.73 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $110.41 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.01 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $43.27 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.00 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $36.67 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.67 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $36.43 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.93 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $28.70 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 94 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 84 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 55 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
94 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 803 | 194 |
| Amlodipine Besylate | Amlodipine Besylate | 587 | 155 |
| Atorvastatin Calcium | Atorvastatin Calcium | 533 | 154 |
| Losartan Potassium | Losartan Potassium | 414 | 110 |
| Omeprazole | Omeprazole | 340 | 105 |
| Gabapentin | Gabapentin | 314 | 77 |
| Alprazolam | Alprazolam | 297 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 282 | 71 |
| Lisinopril | Lisinopril | 264 | 70 |
| Metformin Hcl | Metformin Hcl | 255 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 242 | 79 |
| Simvastatin | Simvastatin | 232 | 61 |
| Furosemide | Furosemide | 223 | 62 |
| Potassium Chloride | Potassium Chloride | 223 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 204 | 58 |
| Diclofenac Sodium | Diclofenac Sodium | 195 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 193 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 189 | 53 |
| Alendronate Sodium | Alendronate Sodium | 183 | 55 |
| Famotidine | Famotidine | 181 | 57 |
| Glimepiride | Glimepiride | 178 | 53 |
| Temazepam | Temazepam | 172 | 33 |
| Carvedilol | Carvedilol | 162 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 160 | 32 |
| Allopurinol | Allopurinol | 148 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 34 |
| Lorazepam | Lorazepam | 137 | 27 |
| Trazodone Hcl | Trazodone Hcl | 132 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 108 | 25 |
| Pregabalin | Pregabalin | 106 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 105 | 45 |
| Sertraline Hcl | Sertraline Hcl | 102 | 31 |
| Warfarin Sodium | Warfarin Sodium | 101 | suppressed |
| Azithromycin | Azithromycin | 95 | 84 |
| Eliquis | Apixaban | 94 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 27 |
| Myrbetriq | Mirabegron | 90 | 13 |
| Jardiance | Empagliflozin | 84 | 23 |
| Clonazepam | Clonazepam | 83 | 12 |
| Clonidine Hcl | Clonidine Hcl | 77 | 18 |
| Meloxicam | Meloxicam | 77 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 75 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 74 | 19 |
| Donepezil Hcl | Donepezil Hcl | 71 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 15 |
| Metformin Hcl Er | Metformin Hcl | 70 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 17 |
| Cefuroxime | Cefuroxime Axetil | 65 | 57 |
| Bumetanide | Bumetanide | 64 | 19 |
| Mupirocin | Mupirocin | 64 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 19 |
| Xarelto | Rivaroxaban | 62 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 51 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 58 | 50 |
| Methocarbamol | Methocarbamol | 56 | 29 |
| Naproxen | Naproxen | 55 | 27 |
| Ozempic | Semaglutide | 55 | 11 |
| Montelukast Sodium | Montelukast Sodium | 54 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 42 |
| Dicyclomine Hcl | Dicyclomine Hcl | 51 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 13 |
| Celecoxib | Celecoxib | 46 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 34 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | suppressed |
| Finasteride | Finasteride | 43 | 13 |
| Cefdinir | Cefdinir | 42 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 13 |
| Mirtazapine | Mirtazapine | 41 | 11 |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | suppressed |
| Estradiol | Estradiol | 38 | 12 |
| Valsartan | Valsartan | 38 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Gemfibrozil | Gemfibrozil | 35 | 11 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Ketoconazole | Ketoconazole | 35 | 21 |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Nystatin | Nystatin | 32 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | 11 |
| Prednisone | Prednisone | 31 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 13 |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 12 |
| Tramadol Hcl | Tramadol Hcl | 28 | 19 |
| Dexlansoprazole Dr | Dexlansoprazole | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 26 | 22 |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 24 |
| Linzess | Linaclotide | 25 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 16 |
| Folic Acid | Folic Acid | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | 16 |
| Promethazine Hcl | Promethazine Hcl | 16 | 15 |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Humulin R | Insulin Regular, Human | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $905.64 · 44 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AIRSUPRA, Cologuard Collection Kit, DAYBUE, ELIQUIS, EVENITY, FARXIGA, Fluad, Flucelvax, GEMTESA, INSPIRE, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, PROLIA, TRELEGY ELLIPTA, VOQUEZNA, VYEPTI, Wegovy, XIFAXAN, ZENPEP, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error